0000950170-24-041844.txt : 20240404 0000950170-24-041844.hdr.sgml : 20240404 20240404163049 ACCESSION NUMBER: 0000950170-24-041844 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240402 FILED AS OF DATE: 20240404 DATE AS OF CHANGE: 20240404 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Burow Kristina CENTRAL INDEX KEY: 0001569248 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41989 FILM NUMBER: 24823526 MAIL ADDRESS: STREET 1: 8755 W. HIGGINS ROAD STREET 2: SUITE 1025 CITY: CHICAGO STATE: IL ZIP: 60631 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Boundless Bio, Inc. CENTRAL INDEX KEY: 0001782303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 830751369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9880 CAMPUS POINT DRIVE STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 766-9912 MAIL ADDRESS: STREET 1: 9880 CAMPUS POINT DRIVE STREET 2: SUITE 120 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 ownership.xml 4 X0508 4 2024-04-02 0001782303 Boundless Bio, Inc. BOLD 0001569248 Burow Kristina C/O BOUNDLESS BIO, INC. 9880 CAMPUS POINT DRIVE, SUITE 120 SAN DIEGO CA 92121 true false true false false Common Stock 2024-04-02 4 C false 589743 A 617092 I See footnotes Common Stock 2024-04-02 4 C false 787545 A 828570 I See footnotes Common Stock 2024-04-02 4 C false 1048433 A 1048433 I See footnotes Common Stock 2024-04-02 4 P false 66667 16.00 A 683759 I See footnotes Common Stock 2024-04-02 4 P false 133333 16.00 A 1181766 I See footnotes Series A Convertible Preferred Stock 2024-04-02 4 C false 424908 D Common Stock 424908 0 I See footnotes Series A Convertible Preferred Stock 2024-04-02 4 C false 586080 D Common Stock 586080 0 I See footnotes Series A Convertible Preferred Stock 2024-04-02 4 C false 454212 D Common Stock 454212 0 I See footnotes Series B Convertible Preferred Stock 2024-04-02 4 C false 227920 D Common Stock 227920 0 I See footnotes Series C Convertible Preferred Stock 2024-04-02 4 C false 164835 D Common Stock 164835 0 I See footnotes Series C Convertible Preferred Stock 2024-04-02 4 C false 201465 D Common Stock 201465 0 I See footnotes Series C Convertible Preferred Stock 2024-04-02 4 C false 366301 D Common Stock 366301 0 I See footnotes Each share of the Issuer's preferred stock is convertible into shares of the Issuer's common stock and has no expiration date. The preferred stock automatically converted into common stock upon the closing of the Issuer's initial public offering. These shares are held directly by ARCH Venture Fund IX, L.P. (ARCH IX). ARCH Venture Partners IX, L.P. (AVP IX LP) is the sole general partner of ARCH IX. These shares are held directly by ARCH Venture Fund IX Overage, L.P. (ARCH IX Overage). ARCH Venture Partners IX Overage, L.P. (AVP IX Overage LP) is the sole general partner of ARCH IX Overage. ARCH Venture Partners IX, LLC (AVP IX LLC) is the sole general partner of each of AVP IX LP and AVP IX Overage LP. Keith Crandell, Robert Nelsen and Clint Bybee are managing directors of AVP IX LLC ("AVP IX MDs"). AVP IX LP and AVP IX Overage LP may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, respectively, AVP IX LLC may be deemed to beneficially own the shares held by ARCH IX and ARCH IX Overage, and the AVP IX MDs may be deemed to share the power to direct the disposition and vote of the shares held by ARCH IX and ARCH IX Overage. AVP IX LP, AVP IX Overage LP, AVP IX LLC and the AVP IX MDs have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any. The Reporting Person has an interest in the AVP IX LP and AVFP IX Overage LP but does not have voting or investment control over the shares held by ARCH IX and ARCH IX Overage. The Reporting Person disclaims ownership of such shares, except to the extent of her pecuniary interest therein. These shares are held directly by ARCH Venture Fund X Overage, L.P. (ARCH X Overage). ARCH Venture Partners X Overage, L.P. (AVP X Overage LP) is the sole general partner of ARCH X Overage. ARCH Venture Partners X, LLC (AVP X LLC) is the sole general partner of AVP X Overage LP. In addition to the Reporting Person, Keith Crandell, Robert Nelsen and Steven Gillis are members of the investment committee of AVP X LLC (the "AVP X Committee Members"). AVP X Overage LP may be deemed to beneficially own the shares held by ARCH X Overage, AVP X LLC may be deemed to beneficially own the shares held by ARCH X Overage, and each of the AVP X Committee Members may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. AVP X Overage LP, AVP X LLC, and the AVP X Committee Members other than the Reprting Person have filed a separate Form 4 and disclaim beneficial ownership except to the extent of any pecuniary interest therein, if any. The Reporting Person is also an AVP X Committee Member and may be deemed to share the power to direct the disposition and vote of the shares held by ARCH X Overage. The Reporting Person disclaims beneficial ownership of such shares except to any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by her for Section 16 or any other purpose. Reflects shares purchased by ARCH IX in the Issuer's initial public offering. Reflects shares purchased by ARCH X Overage in the Issuer's initial public offering. /s/ Jessica Oien, Attorney-in-Fact for Kristina Burow 2024-04-04